ANBL2421

Phase 1/2 Study of Dinutuximab/Cyclophosphamide/Topotecan/Sargramostim (GM-CSF) with or without Iberdomide in Children with Relapsed, Refractory, or Progressive Neuroblastoma Following Prior Chemoimmunotherapy